Krystal Biotech (4KB) Price & Analysis

1 Followers

4KB Stock Chart & Stats

€222.60

€5.15(3.47%)

At close: Jan 08 4:00 PM EST

€222.60

€5.15(3.47%)

Day’s Range― - ―

52-Week Range€115.50 - €330.20

Previous CloseN/A

Volume0.00

Average Volume (3M)12.00

Market Cap

€8.77B

Enterprise Value€7.07K

Total Cash (Recent Filing)€823.40M

Total Debt (Recent Filing)€9.11M

Price to Earnings (P/E)43.8

Beta0.23

Next Earnings

Aug 10, 2026

EPS Estimate

1.51

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)7.75

Shares Outstanding29,479,755

10 Day Avg. Volume13

30 Day Avg. Volume12

Financial Highlights & Ratios

PEG Ratio0.27

Price to Book (P/B)5.85

Price to Sales (P/S)18.34

P/FCF Ratio37.77

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€313.71

Price Target Upside40.93% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

EPS Forecast (FY)6.62

Revenue Forecast (FY)€449.93M

Bulls Say, Bears Say

Bulls Say

Very High Gross MarginsSustained ~95% gross margin indicates durable manufacturing economics for VYJUVEK and strong product pricing power. High gross margins support robust operating leverage, fund ongoing R&D and commercialization, and reduce sensitivity of profitability to modest revenue fluctuations over the next 2–6 months.

Strong Cash Generation & Low LeverageRobust operating cash flow and FCF combined with minimal debt provide a durable financial runway to fund clinical programs, international launches, and working capital needs. Low leverage materially reduces refinancing and solvency risk through near-term regulatory and commercial milestones.

Commercial Traction And Prescriber AdoptionHigh share among identified DEB patients plus expanding prescriber counts and reimbursement approvals signal sticky demand and effective commercial execution. This durable adoption base supports predictable recurring treatments and secular revenue growth as international rollouts progress.

Bears Say

Quarterly Revenue UnpredictabilityFrequent insurance transitions and maintenance-treatment start-stops create persistent quarter-to-quarter revenue volatility and complicate operational planning. Over the medium term this can impair forecasting, working-capital management and the visibility investors and management need to pace launches and spending.

European Pricing & Reimbursement RiskUnresolved pricing negotiations in major EU markets risk delaying launches or reducing realized prices, constraining international revenue growth and long-run margins. Because Europe represents a material expansion opportunity, protracted negotiations pose an enduring execution and access risk over coming quarters.

Short Track Record And Historical VolatilityKrystal's current profitability and cash generation are a recent development following years of losses. That shorter track record increases risk that adverse commercial, reimbursement or clinical setbacks could reintroduce volatility in earnings and cash flow over the medium term.

Krystal Biotech News

Krystal Biotech to replace Taylor Morrison in S&P 400 at open on 7/24

Berkshire Hathaway (BRK.B) (BRK.A) (BRK.A/BRK.B) is acquiring Taylor Morrison Home (TMHC) in a deal expected to close on...

2d ago

KRYS

TMHC

Tutor Perini to replace Krystal Biotech in S&P 600 at open on 7/24

17:18 EDT Tutor Perini (TPC) to replace Krystal Biotech (KRYS) in S&P 600 at open on 7/24 Published...

2d ago

TPC

KRYS

Krystal Biotech price target raised to $396 from $364 at BofA

BofA raised the firm’s price target on Krystal Biotech (KRYS) to $396 from $364 and keeps a Buy...

9d ago

KRYS

Krystal Biotech price target raised to $474 from $399 at Jefferies

Jefferies raised the firm’s price target on Krystal Biotech (KRYS) to $474 from $399 and keeps a Buy...

10d ago

KRYS

Krystal Biotech Updates KB801 Patent Office Filing

The latest update is out from Krystal Biotech ( ($KRYS) ). On July 21, 2026, Krystal Biotech filed...

1d ago

KRYS

Krystal Biotech price target raised to $403 from $306 at TD Cowen

TD Cowen raised the firm’s price target on Krystal Biotech (KRYS) to $403 from $306 and keeps a...

1M ago

KRYS

Krystal Biotech price target raised to $361 from $310 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Krystal Biotech (KRYS) to $361 from $310...

1M ago

KRYS

Krystal Biotech Shareholders Approve Directors and Compensation

Krystal Biotech ( ($KRYS) ) just unveiled an announcement. At its May 15, 2026 annual meeting of stockholders,...

2M ago

KRYS

Analyst Reiterates Buy on Krystal Biotech as Vyjuvek Global Launch and Growing Rare-Disease Pipeline Underpin Long-Term Upside

William Blair analyst Sami Corwin has maintained their bullish stance on KRYS stock, giving a Buy rating today....

2M ago

KRYS

Krystal Biotech announces UK MHRA approval of Vyjuvek

Krystal Biotech (KRYS) announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, granted marketing...

2M ago

KRYS

U.K.’s MHRA approves Krystal’s Vyjuvek for dystrophic epidermolysis bullosa

The Medicines and Healthcare products Regulatory Agency has approved Krystal Biotech’s (KRYS) beremagene geperpavec — Vyjuvek — for...

2M ago

KRYS

Krystal Biotech price target raised to $300 from $295 at Evercore ISI

Evercore ISI raised the firm’s price target on Krystal Biotech (KRYS) to $300 from $295 and keeps an...

3M ago

KRYS

Krystal Biotech price target raised to $378 from $371 at Citi

Citi raised the firm’s price target on Krystal Biotech (KRYS) to $378 from $371 and keeps a Buy...

3M ago

KRYS

Krystal Biotech Earnings Call Highlights Profitable Growth

Krystal Biotech, Inc. (($KRYS)) has held its Q1 earnings call. Read on for the main highlights of the...

3M ago

KRYS

4KB FAQ

What was Krystal Biotech, Inc.’s price range in the past 12 months?

Krystal Biotech, Inc. lowest stock price was €115.50 and its highest was €330.20 in the past 12 months.

What is Krystal Biotech, Inc.’s market cap?

Krystal Biotech, Inc.’s market cap is €8.77B.

When is Krystal Biotech, Inc.’s upcoming earnings report date?

Krystal Biotech, Inc.’s upcoming earnings report date is Aug 10, 2026 which is in 18 days.

How were Krystal Biotech, Inc.’s earnings last quarter?

Krystal Biotech, Inc. released its earnings results on May 04, 2026. The company reported €1.605 earnings per share for the quarter, beating the consensus estimate of €1.307 by €0.298.

Is Krystal Biotech, Inc. overvalued?

According to Wall Street analysts Krystal Biotech, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Krystal Biotech, Inc. pay dividends?

Krystal Biotech, Inc. does not currently pay dividends.

What is Krystal Biotech, Inc.’s EPS estimate?

Krystal Biotech, Inc.’s EPS estimate is 1.51.

How many shares outstanding does Krystal Biotech, Inc. have?

Krystal Biotech, Inc. has 29,479,755 shares outstanding.

What happened to Krystal Biotech, Inc.’s price movement after its last earnings report?

Krystal Biotech, Inc. reported an EPS of €1.605 in its last earnings report, beating expectations of €1.307. Following the earnings report the stock price went up 3.149%.

Which hedge fund is a major shareholder of Krystal Biotech, Inc.?

Currently, no hedge funds are holding shares in DE:4KB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Krystal Biotech Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

30.02%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Krystal Biotech, Inc.

Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States. Its most advanced therapeutic candidate, beremagene geperpavec (B-VEC), is currently undergoing Phase III clinical evaluation for the treatment of dystrophic epidermolysis bullosa. The company's pipeline also includes several other promising programs: KB105 is in Phase I/II clinical trials for patients suffering from deficient autosomal recessive congenital ichthyosis; KB301 is also in Phase I/II development, aiming to ameliorate wrinkles and other signs of aging or damaged skin. Additionally, Krystal Biotech is conducting preclinical research on KB407 for cystic fibrosis and KB104 for Netherton syndrome. In its earlier discovery phase, the company is exploring candidates such as KB5xx for chronic skin conditions and multiple KB3xx programs targeting aesthetic dermatological concerns. Krystal Biotech, Inc. was established in 2015 and is based in Pittsburgh, Pennsylvania.

Krystal Biotech (4KB) Earnings & Revenues

Historic Earnings Reports

4KB Stock 12 Month Forecast

Average Price Target

€313.71

▲(40.93% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"114":"€114","415":"€415","189.25":"€189.3","264.5":"€264.5","339.75":"€339.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":414.32552352,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€414.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":313.70638560000003,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€313.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":248.24567232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€248.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[114,189.25,264.5,339.75,415],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,330.2,336.67119411692306,343.14238823384613,349.6135823507692,356.0847764676923,362.55597058461535,369.0271647015385,375.4983588184615,381.9695529353846,388.4407470523077,394.9119411692308,401.38313528615384,407.8543294030769,{"y":414.32552352,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,330.2,328.9312604307692,327.66252086153844,326.39378129230766,325.12504172307695,323.8563021538462,322.5875625846154,321.3188230153846,320.05008344615385,318.7813438769231,317.51260430769236,316.2438647384616,314.9751251692308,{"y":313.70638560000003,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,330.2,323.8958209476923,317.5916418953846,311.2874628430769,304.98328379076924,298.67910473846155,292.37492568615386,286.07074663384617,279.7665675815385,273.4623885292308,267.1582094769231,260.8540304246154,254.5498513723077,{"y":248.24567232,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":115.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":133.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.05,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":151,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":162.1,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.65,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":214.2,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":237,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":230.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":222.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":219.1,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":260,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":330.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >